The Daily Papule

Clin DermReview

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome

An emerging autoinflammatory paraneoplastic disorder.

Chen R, Fettel K, Sakunchotpanit G, Tran R, Spiegel B, Akbik M, Nambudiri VE

Clinics in DermatologyIn the feed 26 Jul 2026, published online 26 Jul 2026, issue 2026 Sep-Oct, added to PubMed 26 Jul 2026

Topics: Neutrophilic, granulomatous & autoinflammatoryGenetic skin diseaseSkin signs of systemic disease

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a novel autoinflammatory disorder caused by somatic mutations in the UBA1 gene. It predominantly affects older me, although cases in women with X-chromosome mosaicism have been reported in the literature. Dermatologic manifestations, found in up to 90% of cases, are significant diagnostic clues and may include erythematous plaques, Sweet syndrome-like lesions, and livedo reticularis. VEXAS syndrome poses significant diagnostic challenges due to its overlap with hematologic, autoimmune, and inflammatory disease. Hallmark findings include macrocytic anemia, myeloid vacuolization, and the presence of UBA1 mutations. Current treatment options include corticosteroids, biologics, and hematopoietic stem cell transplantation, but data on long-term efficacy are limited. Advances in understanding the epidemiology, pathophysiology, and treatment of VEXAS syndrome will be essential for improving diagnostic accuracy and patient outcomes.

Abstract from PubMed

PMID 42503337 · DOI 10.1016/j.clindermatol.2026.07.024

Comments